Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.
暂无分享,去创建一个
Sheng-Chieh Hsu | Geoffrey Bartholomeusz | Jin-Yuan Shih | J. Shih | M. Hung | W. Xia | Yongkun Wei | Mohamed Ali-Seyed | H. Lo | S. Hsu | G. Bartholomeusz | M. Gunduz | Mien-Chie Hung | Yongkun Wei | Weiya Xia | Hui-Wen Lo | Mehmet Gunduz | Mohamed Ali-Seyed
[1] Y. Soini,et al. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] J. S. Gutkind,et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. , 2003, Cancer research.
[3] J. Darnell,et al. Independent and Cooperative Activation of Chromosomal c-fos Promoter by STAT3* , 2003, The Journal of Biological Chemistry.
[4] R. Schulte‐Hermann,et al. A novel mechanism for mitogenic signaling via pro–transforming growth factor α within hepatocyte nuclei , 2002, Hepatology.
[5] Y. Chan,et al. Neurotrophin receptor immunostaining in the vestibular nuclei of rats , 2003, Neuroreport.
[6] Huang Shao,et al. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.
[7] D. Geller,et al. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. M. Green,et al. Nuclear translocation of IFN-gamma is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[9] T. Hirano,et al. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. , 1999, Immunity.
[10] D. Nathans,et al. In vitro activation of Stat3 by epidermal growth factor receptor kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] P. Subramaniam,et al. Differential Nuclear Localization of the IFNGR-1 and IFNGR-2 Subunits of the IFN-γ Receptor Complex Following Activation by IFN-γ , 2000 .
[12] F. Cianchi,et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. , 2003, The American journal of pathology.
[13] T. Grunt,et al. c-erbB-3 , 2002, The Journal of cell biology.
[14] P. Subramaniam,et al. Lipid Microdomains Are Required Sites for the Selective Endocytosis and Nuclear Translocation of IFN-γ, Its Receptor Chain IFN-γ Receptor-1, and the Phosphorylation and Nuclear Translocation of STAT1α1 , 2002, The Journal of Immunology.
[15] E. Reddy,et al. Elk-1 proteins are phosphoproteins and activators of mitogen-activated protein kinase. , 1993, Cancer research.
[16] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[17] M. Hung,et al. Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors , 2004, Cancer Research.
[18] M. O’connor,et al. Induction and activity of nitric oxide synthase in cultured human intestinal epithelial monolayers. , 1996, The American journal of physiology.
[19] S. Murakami,et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway , 2002, Oncogene.
[20] T. Hirano,et al. A central role for Stat3 in IL‐6‐induced regulation of growth and differentiation in M1 leukemia cells. , 1996, The EMBO journal.
[21] B. Barre,et al. Opposite Regulation of Myc and p21 waf1 Transcription by STAT3 Proteins* , 2003, The Journal of Biological Chemistry.
[22] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[23] P. Maher. Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2 , 1996, The Journal of cell biology.
[24] J. Abbruzzese,et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.
[25] M. Hung,et al. Systemic tumor suppression by the proapoptotic gene bik. , 2002, Cancer research.
[26] A. Orucevic,et al. Role of nitric oxide in tumor progression: Lessons from experimental tumors , 1998, Cancer and Metastasis Reviews.
[27] M. Hung,et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.
[28] J. Turkson,et al. Cytoplasmic transport of Stat3 by receptor‐mediated endocytosis , 2002, The EMBO journal.
[29] P Rhodes,et al. Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[30] P. Heinrich,et al. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level , 1993, Molecular and cellular biology.
[31] F. Cianchi,et al. Cyclooxygenase-2 Activation Mediates the Proangiogenic Effect of Nitric Oxide in Colorectal Cancer , 2004, Clinical Cancer Research.
[32] P. Coffer,et al. EGF receptor deletions define a region specifically mediating STAT transcription factor activation. , 1995, Biochemical and biophysical research communications.
[33] J. Massagué,et al. OAZ Uses Distinct DNA- and Protein-Binding Zinc Fingers in Separate BMP-Smad and Olf Signaling Pathways , 2000, Cell.
[34] S. Hsu,et al. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[35] G. Rassidakis,et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] R. Jove,et al. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.
[37] T. Fitzgerald,et al. Differential expression of nitric oxide synthases in EGF-responsive mouse neural precursor cells , 1999, Cell and Tissue Research.
[38] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[39] J. Mouscadet,et al. The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[40] L. Magnelli,et al. Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. , 2002, Biochemical and biophysical research communications.
[41] M. Hung,et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. , 2005, Cancer research.
[42] J. Turkson,et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling , 2000, Oncogene.
[43] A. Hamburger,et al. ErbB‐2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells , 1999, International journal of cancer.
[44] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[45] R. Roeder,et al. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.
[46] E. Qwarnstrom,et al. IL-1 and its receptor are translocated to the nucleus. , 1990, Journal of immunology.
[47] A. Bridges,et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.
[48] C. Rao,et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. , 2002, Cancer research.
[49] J. Hsuan,et al. EGF receptors as transcription factors: ridiculous or sublime? , 2001, Nature Cell Biology.
[50] M. Moran,et al. Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. , 1990, Science.
[51] E. Rimm,et al. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.
[52] J. Baselga,et al. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] M. Barker,et al. Localization of epidermal growth factor receptor in hepatocyte nuclei , 1991, Hepatology.
[54] Hua Yu,et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.
[55] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[56] K. Yung,et al. Receptors of Glutamate and Neurotrophin in Vestibular Neuronal Functions , 2003, Journal of Biomedical Science.
[57] M. Masuda,et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.
[58] M. Hung,et al. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .
[59] Michael Chinkers,et al. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. , 1982, The Journal of biological chemistry.
[60] F. Xy. From PTK-STAT signaling to caspase expression and apoptosis induction. , 1999 .
[61] D. Jans,et al. Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling? , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[62] W. Cance,et al. A decade of tyrosine kinases: from gene discovery to therapeutics. , 2003, Surgical oncology.
[63] A. Buzaid,et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[64] T. Golde,et al. γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.
[65] A. Dowlati,et al. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. , 2004, Molecular cancer therapeutics.
[66] D. Jans,et al. The cytokine interleukin‐5 (IL‐5) effects cotransport of its receptor subunits to the nucleus in vitro , 1997, FEBS letters.
[67] M. Hung,et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[68] G. Devries,et al. Localization of neuregulin isoforms and erbB receptors in myelinating glial cells , 2004, Glia.
[69] A. Shiau,et al. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis , 2003, British Journal of Cancer.
[70] H. Hauser,et al. Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: The role of NF-κB-repressing factor (NRF) in basal repression of the hiNOS gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[71] P. Lala,et al. Animal Model Nitric Oxide Synthase Inhibition by N G -Nitro- L Arginine Methyl Ester Inhibits Tumor-Induced Angiogenesis in Mammary Tumors , 1999 .
[72] T. Bader,et al. Nuclear accumulation of interferon gamma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[73] P. Maher,et al. Importin β–Mediated Nuclear Import of Fibroblast Growth Factor Receptor , 2001, The Journal of Cell Biology.
[74] D. Johnston,et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] M. Herlyn,et al. Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. , 1988, Cancer research.
[76] M. O’Connor-McCourt,et al. Predominant intracellular localization of the type I transforming growth factor-beta receptor and increased nuclear accumulation after growth arrest. , 2000, Experimental cell research.
[77] A. Ullrich,et al. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors , 1992, Molecular and cellular biology.
[78] A. Vannacci,et al. The MDR phenotype is associated with the expression of COX‐2 and iNOS in a human hepatocellular carcinoma cell line , 2002, Hepatology.
[79] Frank E. Jones,et al. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone , 2004, The Journal of cell biology.
[80] J. Olefsky,et al. Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects. , 1987, The Journal of biological chemistry.
[81] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[82] J. Reichrath,et al. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. , 2002, Anticancer research.
[83] Teresa Reguly,et al. In or out? The dynamics of Smad nucleocytoplasmic shuttling. , 2003, Trends in cell biology.
[84] A. Wells,et al. Signalling shortcuts: cell-surface receptors in the nucleus? , 2002, Nature Reviews Molecular Cell Biology.
[85] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[86] Bin Liu,et al. Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy , 2003, Neurobiology of Disease.
[87] M. Hung,et al. Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. , 1994, Biochemical and biophysical research communications.
[88] Carlos Arteaga,et al. Targeting HER1/EGFR: a molecular approach to cancer therapy. , 2003, Seminars in oncology.
[89] J. Turkson,et al. STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.
[90] R. Jove,et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.
[91] J. Baselga,et al. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. , 2001, Seminars in oncology.
[92] S. Cohen,et al. Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[93] P. Farnham,et al. The identification of E2F1-specific target genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[94] U. Marti,et al. Acinar and cellular distribution and mRNA expression of the epidermal growth factor receptor are changed during liver regeneration. , 1995, Journal of hepatology.
[95] C. Arteaga,et al. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.
[96] T. Yeatman,et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.